Dr. David Greene and R3 Stem Cell Achieve IRB Approval for Regenerative Therapies

Monday, May 13, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Dr. David Greene and R3 Stem Cell have achieved IRB Approval for regenerative therapies. The approval is the only one of its kind in the United States and practices nationwide may participate with R3.

SCOTTSDALE, Ariz., May 13, 2019 /PRNewswire-PRWeb/ -- Dr. David Greene and R3 Stem Cell

have achieved IRB Approval for regenerative therapies. The approval is the only one of its kind in the United States and practices nationwide may participate with R3.

An IRB, which is short for Institutional Review Board, is an accredited agency that reviews research protocols to ensure proper safety protocols are in place and that the benefits of therapies far outweigh the risks. In addition, an IRB reviews all of the paperwork associated with each study to make sure it is written in language that patients can easily understand and it is thorough.

Said CEO Dr. David Greene, "Our goal with the regenerative therapies is to help patients with procedures that are not only effective, but also super safe. We are the only company in the US to seek out IRB approval for umbilical and amniotic therapies, with protocols for seven different condition categories!"

The regenerative procedures involve the use of stem cells, growth factors, exosomes, secretomes and microRNA for conditions including musculoskeletal, autoimmune, cardiac, pulmonary, renal, urologic and neurologic. Conditions underneath each category are broad and may include COPD, rheumatoid or osteoarthritis, post-stroke, erectile dysfunction, Alzheimer's, lupus, and cardiomyopathy.

Each patient receives a specific regenerative therapy that is individualized for each condition category. Patients are then followed up at regular intervals for several years, evaluating improvements with questionnnaires specific to the condition.

"To date, our nationwide Centers have collectively performed over 10,000 regenerative cell therapies. The umbilical cord stem cell therapy procedures have not only been safe, but very effective. We want to get more data in a structured format," continued Dr. Greene.

R3 is always looking for more quality practices to join its network. Those interested should visit https://r3stemcell.com and contact Dr. Greene at (844) GET-STEM. Stem cell marketing is also offered through the company.

Disclaimer: The information provided by R3 Stem Cell is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and only one's medical professional can explain all the risks and potential benefits of any therapy based on one's circumstances. R3 Stem Cell does not recommend or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on its website. The FDA considers stem cell therapy experimental at this point.

 

SOURCE US Lead Network



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store